Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 783

1.

Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.

Karkeni E, Morin SO, Bou Tayeh B, Goubard A, Josselin E, Castellano R, Fauriat C, Guittard G, Olive D, Nunès JA.

Front Immunol. 2019 Jun 6;10:1307. doi: 10.3389/fimmu.2019.01307. eCollection 2019.

2.

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

Incorvaia L, Badalamenti G, Rinaldi G, Iovanna JL, Olive D, Swayden M, Terruso L, Vincenzi B, Fulfaro F, Bazan V, Russo A, Fanale D.

Ther Adv Med Oncol. 2019 May 13;11:1758835919848872. doi: 10.1177/1758835919848872. eCollection 2019.

3.

A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system.

Burlion A, Ramos RN, Kc P, Sendeyo K, Corneau A, Ménétrier-Caux C, Piaggio E, Olive D, Caux C, Marodon G.

Oncoimmunology. 2019 Apr 12;8(7):1596005. doi: 10.1080/2162402X.2019.1596005. eCollection 2019.

4.

Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function.

Degos C, Heinemann M, Barrou J, Boucherit N, Lambaudie E, Savina A, Gorvel L, Olive D.

Front Immunol. 2019 Apr 26;10:877. doi: 10.3389/fimmu.2019.00877. eCollection 2019.

5.

An X-ray Vision for Phosphoantigen Recognition.

Dustin ML, Scotet E, Olive D.

Immunity. 2019 Apr 16;50(4):1026-1028. doi: 10.1016/j.immuni.2019.03.015.

PMID:
30995494
6.

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.

Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien AS, Incorvaia L, Russo A, Olive D, Iovanna J.

Oncoimmunology. 2019 Feb 3;8(4):e1561120. doi: 10.1080/2162402X.2018.1561120. eCollection 2019.

7.

Two Modest Proposals: Thoughts from the Myoma/Leiomyosarcoma Controversies.

Olive DL.

J Minim Invasive Gynecol. 2019 Mar 20. pii: S1553-4650(19)30131-1. doi: 10.1016/j.jmig.2019.03.010. [Epub ahead of print] No abstract available.

PMID:
30904485
8.

PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua.

Vacca P, Pesce S, Greppi M, Fulcheri E, Munari E, Olive D, Mingari MC, Moretta A, Moretta L, Marcenaro E.

Mucosal Immunol. 2019 May;12(3):624-631. doi: 10.1038/s41385-019-0141-9. Epub 2019 Feb 12.

PMID:
30755717
9.

Fonctions de CD28, CTLA-4 et PD-1.

Olive D.

Bull Cancer. 2018 Dec;105 Suppl 1:S3-S15. doi: 10.1016/S0007-4551(18)30385-0. French.

PMID:
30595196
10.

PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.

Heskamp S, Wierstra PJ, Molkenboer-Kuenen JDM, Sandker GW, Thordardottir S, Cany J, Olive D, Bussink J, Boerman OC, Dolstra H, Aarntzen EHJG, Hobo WA.

Cancer Immunol Res. 2019 Jan;7(1):150-161. doi: 10.1158/2326-6066.CIR-18-0280. Epub 2018 Nov 20.

PMID:
30459153
11.

T lymphocyte subsets in cancer immunity: Friends or foes.

Chraa D, Naim A, Olive D, Badou A.

J Leukoc Biol. 2019 Feb;105(2):243-255. doi: 10.1002/JLB.MR0318-097R. Epub 2018 Nov 2. Review.

PMID:
30387907
12.

CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas.

Le KS, Amé-Thomas P, Tarte K, Gondois-Rey F, Granjeaud S, Orlanducci F, Foucher ED, Broussais F, Bouabdallah R, Fest T, Leroux D, Yadavilli S, Mayes PA, Xerri L, Olive D.

Blood Adv. 2018 Aug 14;2(15):1889-1900. doi: 10.1182/bloodadvances.2018017244.

13.

New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity.

Blazquez JL, Benyamine A, Pasero C, Olive D.

Front Immunol. 2018 Jul 11;9:1601. doi: 10.3389/fimmu.2018.01601. eCollection 2018. Review.

14.

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.

Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D.

Front Immunol. 2018 May 14;9:1044. doi: 10.3389/fimmu.2018.01044. eCollection 2018. Review.

15.

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.

Le Roy A, Prébet T, Castellano R, Goubard A, Riccardi F, Fauriat C, Granjeaud S, Benyamine A, Castanier C, Orlanducci F, Ben Amara A, Pont F, Fournié JJ, Collette Y, Mege JL, Vey N, Olive D.

Front Immunol. 2018 May 4;9:977. doi: 10.3389/fimmu.2018.00977. eCollection 2018.

16.

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.

Faure M, Rochigneux P, Olive D, Taix S, Brenot-Rossi I, Gilabert M.

Front Immunol. 2018 Apr 19;9:797. doi: 10.3389/fimmu.2018.00797. eCollection 2018.

17.

Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation".

Parker WH, Berek JS, Pritts EA, Olive D, Chalas E, Clarke-Pearson D.

J Minim Invasive Gynecol. 2018 Sep - Oct;25(6):1113. doi: 10.1016/j.jmig.2018.04.008. Epub 2018 Apr 18. No abstract available.

PMID:
29679676
18.

The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells.

Janovec V, Aouar B, Font-Haro A, Hofman T, Trejbalova K, Weber J, Chaperot L, Plumas J, Olive D, Dubreuil P, Nunès JA, Stranska R, Hirsch I.

Front Immunol. 2018 Feb 26;9:364. doi: 10.3389/fimmu.2018.00364. eCollection 2018.

19.

Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.

Borie C, Mondal S, Arif T, Briand M, Lingua H, Dumur F, Gigmes D, Stocker P, Barbarat B, Robert V, Nicoletti C, Olive D, Maresca M, Nechab M.

Eur J Med Chem. 2018 Mar 25;148:306-313. doi: 10.1016/j.ejmech.2018.02.030. Epub 2018 Feb 12.

PMID:
29471119
20.

Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.

Amatore F, Gorvel L, Olive D.

Expert Opin Ther Targets. 2018 Apr;22(4):343-351. doi: 10.1080/14728222.2018.1444753. Epub 2018 Mar 1. Review.

PMID:
29468927
21.

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).

Benyamine A, Loncle C, Foucher E, Blazquez JL, Castanier C, Chrétien AS, Modesti M, Secq V, Chouaib S, Gironella M, Vila-Navarro E, Montalto G, Dagorn JC, Dusetti N, Iovanna J, Olive D.

Oncoimmunology. 2017 Sep 21;7(1):e1372080. doi: 10.1080/2162402X.2017.1372080. eCollection 2017.

22.

Alternative facts and morcellation.

Olive DL.

Curr Opin Obstet Gynecol. 2018 Feb;30(1):60-64. doi: 10.1097/GCO.0000000000000436. Review.

PMID:
29227303
23.

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.

Chretien AS, Devillier R, Fauriat C, Orlanducci F, Harbi S, Le Roy A, Rey J, Bouvier Borg G, Gautherot E, Hamel JF, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Blaise D, Olive D.

Oncoimmunology. 2017 Mar 24;6(12):e1307491. doi: 10.1080/2162402X.2017.1307491. eCollection 2017.

24.

Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation".

Parker WH, Berek JS, Pritts EA, Olive D, Chalas E, Clarke-Pearson D.

J Minim Invasive Gynecol. 2018 Jan;25(1):187-188. doi: 10.1016/j.jmig.2017.07.027. Epub 2017 Aug 18. No abstract available.

PMID:
28826956
25.

NKG2C+ memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147.

Gondois-Rey F, Chéret A, Granjeaud S, Mallet F, Bidaut G, Lécuroux C, Ploquin M, Müller-Trutwin M, Rouzioux C, Avettand-Fenoël V, Moretta A, Pialoux G, Goujard C, Meyer L, Olive D.

Clin Transl Immunology. 2017 Jul 7;6(7):e150. doi: 10.1038/cti.2017.22. eCollection 2017 Jul.

26.

Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model.

Burlion A, Brunel S, Petit NY, Olive D, Marodon G.

Front Immunol. 2017 Jun 30;8:756. doi: 10.3389/fimmu.2017.00756. eCollection 2017.

27.

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.

Chretien AS, Fauriat C, Orlanducci F, Galseran C, Rey J, Bouvier Borg G, Gautherot E, Granjeaud S, Hamel-Broza JF, Demerle C, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Gregori E, Luche H, Malissen M, Arnoulet C, Nunes JA, Vey N, Olive D.

Front Immunol. 2017 May 29;8:573. doi: 10.3389/fimmu.2017.00573. eCollection 2017.

28.

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.

Spodzieja M, Lach S, Iwaszkiewicz J, Cesson V, Kalejta K, Olive D, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowidło S.

PLoS One. 2017 Jun 8;12(6):e0179201. doi: 10.1371/journal.pone.0179201. eCollection 2017.

29.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D.

Oncotarget. 2017 Jul 25;8(30):49548-49563. doi: 10.18632/oncotarget.17747.

30.

Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.

Djaoud Z, Guethlein LA, Horowitz A, Azzi T, Nemat-Gorgani N, Olive D, Nadal D, Norman PJ, Münz C, Parham P.

J Exp Med. 2017 Jun 5;214(6):1827-1841. doi: 10.1084/jem.20161017. Epub 2017 May 3.

31.

The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human Vγ9Vδ2 T Cells.

Peigné CM, Léger A, Gesnel MC, Konczak F, Olive D, Bonneville M, Breathnach R, Scotet E.

J Immunol. 2017 Jun 1;198(11):4228-4234. doi: 10.4049/jimmunol.1601910. Epub 2017 May 1.

32.

NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27.

Dondero A, Casu B, Bellora F, Vacca A, De Luisi A, Frassanito MA, Cantoni C, Gaggero S, Olive D, Moretta A, Bottino C, Castriconi R.

Oncotarget. 2017 May 23;8(21):35088-35102. doi: 10.18632/oncotarget.17070.

33.

Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.

Xerri L, Huet S, Venstrom JM, Szafer-Glusman E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Laurent C, Gelas-Dore B, Bolen CR, Punnoose E, Bouabdallah R, Brice P, Morschhauser F, Cartron G, Olive D, Salles G; a LYSA study.

Hum Pathol. 2017 Jun;64:128-136. doi: 10.1016/j.humpath.2017.03.023. Epub 2017 Apr 13.

PMID:
28414090
34.

Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation.

Starick L, Riano F, Karunakaran MM, Kunzmann V, Li J, Kreiss M, Amslinger S, Scotet E, Olive D, De Libero G, Herrmann T.

Eur J Immunol. 2017 Jun;47(6):982-992. doi: 10.1002/eji.201646818. Epub 2017 Apr 27.

35.

Evolutionary and polymorphism analyses reveal the central role of BTN3A2 in the concerted evolution of the BTN3 gene family.

Afrache H, Pontarotti P, Abi-Rached L, Olive D.

Immunogenetics. 2017 Jun;69(6):379-390. doi: 10.1007/s00251-017-0980-z. Epub 2017 Apr 5.

PMID:
28382515
36.

A Mature NK Profile at the Time of HIV Primary Infection Is Associated with an Early Response to cART.

Gondois-Rey F, Chéret A, Mallet F, Bidaut G, Granjeaud S, Lécuroux C, Ploquin M, Müller-Trutwin M, Rouzioux C, Avettand-Fenoël V, De Maria A, Pialoux G, Goujard C, Meyer L, Olive D.

Front Immunol. 2017 Feb 10;8:54. doi: 10.3389/fimmu.2017.00054. eCollection 2017.

37.

Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells.

Rey J, Fauriat C, Kochbati E, Orlanducci F, Charbonnier A, D'Incan E, Andre P, Romagne F, Barbarat B, Vey N, Olive D.

Front Immunol. 2017 Feb 2;8:64. doi: 10.3389/fimmu.2017.00064. eCollection 2017.

38.

Abdominal vs Minimally Invasive Hysterectomy.

Pritts EA, Olive DL, Clarke-Pearson D.

JAMA. 2016 Dec 27;316(24):2677. doi: 10.1001/jama.2016.17819. No abstract available.

PMID:
28027360
39.

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.

M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G, Collette Y, Viens P, Gonçalves A, Ginestier C, Charafe-Jauffret E, Birnbaum D, Olive D, Bertucci F, Lopez M.

Ann Oncol. 2017 Apr 1;28(4):769-776. doi: 10.1093/annonc/mdw678.

PMID:
27998973
40.

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.

Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, Pouyet L, Goubard A, Collette Y, Vey N, Scotet E, Castellano R, Olive D.

Oncoimmunology. 2016 Apr 25;5(10):e1146843. eCollection 2016.

41.

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.

Beldi-Ferchiou A, Lambert M, Dogniaux S, Vély F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbé C, Sène D, Hivroz C, Caillat-Zucman S.

Oncotarget. 2016 Nov 8;7(45):72961-72977. doi: 10.18632/oncotarget.12150.

42.

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D.

Oncoimmunology. 2016 May 19;5(7):e1186323. doi: 10.1080/2162402X.2016.1186323. eCollection 2016 Jul.

43.

Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations.

Nerdal PT, Peters C, Oberg HH, Zlatev H, Lettau M, Quabius ES, Sousa S, Gonnermann D, Auriola S, Olive D, Määttä J, Janssen O, Kabelitz D.

J Immunol. 2016 Oct 15;197(8):3059-3068. Epub 2016 Sep 12.

44.

Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.

Lopez M, Ghidouche A, Rochas C, Godelaine D, Carrasco J, Colau D, Hames G, Montero-Julian FA, Coulie PG, Olive D.

Cancer Immunol Immunother. 2016 Oct;65(10):1177-88. doi: 10.1007/s00262-016-1877-7. Epub 2016 Aug 11.

PMID:
27514672
45.

Coxiella burnetii Induces Inflammatory Interferon-Like Signature in Plasmacytoid Dendritic Cells: A New Feature of Immune Response in Q Fever.

Ka MB, Mezouar S, Ben Amara A, Raoult D, Ghigo E, Olive D, Mege JL.

Front Cell Infect Microbiol. 2016 Jun 27;6:70. doi: 10.3389/fcimb.2016.00070. eCollection 2016.

46.

Agility in adversity: Vaccines on Demand.

De Groot AS, Moise L, Olive D, Einck L, Martin W.

Expert Rev Vaccines. 2016 Sep;15(9):1087-91. doi: 10.1080/14760584.2016.1205951. Epub 2016 Jul 18. Review.

PMID:
27389971
47.

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization.

Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E.

J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3. doi: 10.1016/j.jaci.2016.04.025. Epub 2016 May 27.

PMID:
27372564
48.

A Macrocyclic Chelator That Selectively Binds Ln4+ over Ln3+ by a Factor of 1029.

Pham TA, Altman AB, Stieber SC, Booth CH, Kozimor SA, Lukens WW, Olive DT, Tyliszczak T, Wang J, Minasian SG, Raymond KN.

Inorg Chem. 2016 Oct 17;55(20):9989-10002. Epub 2016 Jun 24.

PMID:
27341328
49.

Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects.

Olive D, Savoldo B, Pastorino F, Castriconi R.

J Immunol Res. 2016;2016:7853028. doi: 10.1155/2016/7853028. Epub 2016 Jun 1. No abstract available.

50.

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?

Cantoni C, Huergo-Zapico L, Parodi M, Pedrazzi M, Mingari MC, Moretta A, Sparatore B, Gonzalez S, Olive D, Bottino C, Castriconi R, Vitale M.

J Immunol Res. 2016;2016:4684268. doi: 10.1155/2016/4684268. Epub 2016 May 12. Review.

Supplemental Content

Support Center